Subtle caspase activation is associated with the differentiation of several myeloid lineages. A tightly orchestrated dance between caspase-3 activation and the chaperone HSP70 that migrates to the nucleus to protect the master regulator GATA-1 from cleavage transiently occurs in basophilic erythroblasts and may prepare nucleus and organelle expel that occurs at the terminal phase of erythroid differentiation. A spatially restricted activation of caspase-3 occurs in maturing megakaryocytes to promote proplatelet maturation and platelet shedding in the bloodstream. In a situation of acute platelet need, caspase-3 could be activated in response to IL-1α and promote megakaryocyte rupture. In peripheral blood monocytes, colony-stimulating factor-1 provokes the formation of a molecular platform in which caspase-8 is activated, which downregulates nuclear factor-kappa B (NF-κB) activity and activates downstream caspases whose target fragments such as those generated by nucleophosmin (NPM1) cleavage contribute to the generation of resting macrophages. Human monocytes secrete mature IL-1β in response to lipopolysaccharide through an alternative inflammasome activation that involves caspase-8, a pathway that does not lead to cell death. Finally, active caspase-3 is part of the proteases contained in secretory granules of mast cells. Many questions remain on how these proteases are activated in myeloid cell lineages, which target proteins are cleaved, whereas other are protected from proteolysis, the precise role of cleaved proteins in cell differentiation and functions, and the link between these non-apoptotic functions of caspases and the death of these diverse cell types. Better understanding of these functions may generate therapeutic strategies to control cytopenias or modulate myeloid cell functions in various pathological situations.
Open Questions
How caspases are activated in erythroid cells and megakaryocytes in response to erythropoietin and thrombopoietin, respectively?
What are the functions of proteins cleaved by caspases in erythroid cells, megakaryocytes and CSF-1-treated monocytes undergoing differentiation? Could we manipulate therapeutically caspase activity to promote some lineage differentiation or modulate macrophage polarization?
The highly regenerative hematopoietic tissue, which produces approximately one trillion cells every day within a human adult bone marrow, is viewed as a hierarchical system with hematopoietic stem cells (HSCs) at the apex. In addition to self-renewing, these multipotent cells give rise to all blood cell lineages through generating a pool of oligopotent progenitor cells that undergo a gradual fate restriction and finally assume the identity of a mature cell circulating in the blood. 1 This roadmap was recently challenged by the results of single cell and family tracing analyses ( Figure 1 ). [2] [3] [4] [5] Whatever the detailed routes of lineage development, apoptosis is part of the process as T-cell maturation includes the eradication of 98% of thymocytes, 6 autoreactive B-lymphocytes are eliminated in the bone marrow 7 and loss of function in the apoptotic cascade alters hematopoietic tissue development while increasing cancer susceptibility. 8 The maintenance of homeostatic cell numbers implicates that the continuous removal of ageing mature cells matches with the production of new cells. Apoptotic caspases are involved in the removal of a number of aged or altered blood cells, these dying cells being cleared by macrophages of the liver, spleen and bone marrow. Apoptosis is the final stage of the short neutrophil and eosinophil life span. 9, 10 Erythrocytes typically undergo senescence and are cleared by the reticuloendothelial system after 100-120 days. 11 These cells may also enter a suicidal death process called eryptosis that could involve caspases despite the lack of mitochondria and Apaf-1 adaptor molecule. 12 Even platelets, which are anuclear cytoplasmic fragments with a 10-days life span, are programmed to die through a caspase-dependent apoptotic process that is activated when Bcl-X L expression declines. 13 Behind apoptotic caspases, inflammatory caspases can be activated in progenitors 14 and mature 15 hematopoietic cells when pattern-recognition receptors interact with pathogen-or damage-associated molecular patterns. This interaction promotes the formation of inflammasomes in which the cytokines interleukin-1β and interleukin-18 are cleaved to be activated and released to eventually promote non-apoptotic inflammatory cell deaths such as pyroptosis and necroptosis. 16 These events interfere with emergency hematopoiesis in response to systemic infections and could drive clonal expansion in myelodysplastic syndromes (MDS). 17 Caspases are also positive and negative regulators of T-cell, B-cell and NK-cell proliferation and activation (Figure 1) , 18, 19 as they contribute to NF-κB activation, 20 cytokine production and apoptosis. Finally, caspases exert subtle non-apoptotic, non-inflammatory functions in the differentiation of several myeloid lineages. These functions are the focus of this review that Figure 1 Currently prevalent scheme of hematopoiesis, showing in red the differentiation steps in which caspase activity is involved. CLP, common lymphoid progenitor; CMP, common myeloid progenitor; GMP, granulocyte-monocyte progenitor; HSC, hematopoietic stem cell; MEP, megakaryocyte-erythroid progenitor; MPP, hematopoietic multipotent progenitor
shows that low-level and transient enzyme activity, chaperoning of proteins whose cleavage would lead to cell death and spatial restriction of activated caspases distinguish caspase activation in differentiating and dying cells.
Caspases in Erythroid Cell Differentiation
According to the prevalent scheme of hematopoiesis, multipotent progenitors (MPP) derived from HSCs give rise to intermediate lineage-restricted progenitors, including common myeloid progenitors (CMP) that generate both granulocyte-macrophage (GMP) and megakaryocyte (MK)-erythroid progenitors (MEP; Figure 1 ). The later progenitors give rise to unipotent erythroid progenitors, with colony assays distinguishing early burst-forming unit -erythroid (BFU-E) from later colony-forming unit -erythroid (CFU-E) progenitors. 21 The earliest morphologically recognizable erythroid precursor is the proerythroblast, which undergoes successive mitosis, each of them producing a morphologically distinct population of erythroblasts, beginning with proerythroblasts and followed by basophilic, polychromatic, and orthochromatic erythroblasts that expel their organelles and nuclei to generate reticulocytes. This ordered differentiation process is accompanied by decreases in cell size, enhanced chromatin condensation, progressive hemoglobinization and marked changes in membrane. 22 Synergistically with stem cell factor (SCF), erythropoietin (Epo) regulates red cell production rate through rescuing a number of erythroid progenitors and early precursors from caspase-mediated apoptosis (Box 1). Epo also positively regulates erythropoiesis by stimulating proliferation and differentiation of erythroid progenitors through upregulation of the zinc finger hematopoietic transcription factor, GATA-1 (GATA-binding factor 1). Neither SCF nor Epo are needed for late steps of erythroid differentiation, from polychromatic erythroblasts to reticulocytes.
While the apoptotic function of caspases is required for the negative regulation of erythroid cell differentiation, the transient activation of caspase-3 and possibly other caspases is required for normal erythroblast maturation (Figures 1, 2a and 3a, Table 1 ). [23] [24] [25] [26] This assertion is based on the ability of pan-caspase inhibitors to block erythroid development at the basophilic stage of maturation, the demonstration of procaspase-3 cleavage in erythroid precursors, and the cleavage of caspase-specific peptide substrates in differentiating erythroid cells (Table 1) . [25] [26] [27] Caspase-3 knock-out mouse models demonstrate distinct phenotypes, depending on their genetic background 28, 29 and the ability of one of them to reach adulthood without defective erythropoiesis questioned the role of caspase-3 in erythroid differentiation. 29 However, redundancies exist between caspases and ablation of caspase-3 by small interfering RNA could block erythropoiesis in a large fraction of the erythroblasts in culture. 24 Several proteins are cleaved by caspases in differentiating erythroblasts (Table 1) , including the kinases ROCK-1 and MEKK1, lamin B, Acinus, ICAD (Inhibitor of caspase-activated DNase), and hnRNP K (heterogeneous nuclear ribonucleoprotein K). 25, 26, [30] [31] [32] [33] ROCK-1 activating cleavage occurs when the SCF/c-KIT-mediated activation of the Rho/RACK signaling pathway is fading, due to the downregulation of c-KIT, and active ROCK-1 phosphorylates the light chain of myosin II. 31 Another kinase cleaved and activated by caspase-3 is MEKK1 that, in turn, activates MEK6/p38α pathway. 30 How these kinases contribute to erythroid differentiation remains unknown. Caspases may be involved in the timely controlled lost of organelles that characterizes terminal erythroid differentiation, for example the cleavage of hnRNP K induces the synthesis of reticulocyte 15-lipooxygenase (r15-LOX) that is needed for the degradation of mitochondria in reticulocytes. 33 One of the characteristic features of erythropoiesis in mammals is a dramatic nuclear condensation observed in orthochromatic erythroblasts and the subsequent extrusion of the nucleus. 34 shRNA knockdown of caspase-3 in human erythroid cells significantly reduces the number of enucleated cells. 24 DNase IIα 35 and Acinus 26 could be the endonucleases responsible for chromatin condensation. Recently, caspase-3 was shown to be required for transient and repeated nuclear opening that occurs in differentiating erythroid cells until just before enucleation, are tightly linked with the cell cycle and permit the selective release of core and linker histones in the cytoplasm where they aggregate around the nuclear opening before being rapidly degraded by the proteasome machinery. 36 Pharmacologic or genetic loss of function of caspase-3 blocks nuclear opening and nuclear condensation, restores nuclear histone H2B, repairs nuclear openings and abrogates new opening formation. 37, 38 Nuclei expelled from Box 1 Epo regulates red cell production rate through rescuing erythroid progenitors and early precursors from apoptosis
Induction of Bcl-X L expression by EpoR-activated STAT5 is a major survival pathway in erythroblasts, [113] [114] [115] which is associated with the ERK-induced degradation of the pro-apoptotic protein Bim. 116 An intracellular Spi2A serpin, which inhibits lysosomal cathepsins, is another Epo/STAT5 cytoprotective target that protects erythroblasts from radical oxygen species toxic effects. 117 Splenic early erythroblasts could also negatively regulate their own survival by co-expressing the death receptor Fas and its ligand, FasL. This regulatory loop accelerates the response to hypoxic stress that otherwise requires a delay for the maturation of Epo-responsive progenitors mature into red cells. 118, 119 Fas ligation results in the activation of caspase-8, then caspase-3, and the cleavage of SCL/Tal-1 120 and GATA-1 118 transcription factors whose inactivation induces a maturation arrest at the basophilic erythroblast stage and cell death by apoptosis. erythroid precursor cells quickly expose phosphatidylserine on their surface and are engulfed by macrophages. 39 Importantly, the transcriptional factor GATA-1, which is degraded by caspases in erythroid cells undergoing apoptosis upon cytokine starvation or exposure to death receptor ligands, 40 remains uncleaved in differentiating erythroblasts ( Figure 3a ). GATA-1 plays a central role in Epo-mediated upregulation of genes involved in erythroid cell differentiation, including EpoR, α-globin and glycophorin A genes 41 and in erythroid cell survival, mainly Bcl-X L . 42 The chaperone protein HSP70 translocates to the nucleus at the onset of caspase activation to physically interact with, and protect GATA-1 from caspase-mediated proteolysis (Figure 3a ). GATA-1 is cleaved by caspase-3 when HSP70 is downregulated in erythroid precursors cultured in the presence of Epo, which leads to the downregulation of Bcl-X L and cell death by apoptosis. Epo starvation induces the nuclear export of Hsp70, exposing GATA-1 to caspase-mediated proteolysis. 43 Deregulation of the interplay between HSP70, GATA-1 and caspases may account for the anemia that develops in some MDS 44, 45 and β-thalassaemia 46 (Box 2). At the end of erythroid differentiation, GATA-1 expression level and activity decrease. 47 To finetune GATA-1 expression, another chaperone, HSP27 binds in its p38-phosphorylated form to acetylated GATA-1 to promote its ubiquitination and proteasomal degradation. 48 
Caspases in Proplatelet Formation and Platelet Release
Thrombopoietin (TPO) interacting with its receptor MPL promotes the conversion of HSCs and multipotent progenitors into MK progenitors 2, 4 (Table 1) whose terminal differentiation includes a switch from mitosis to endomitosis to generate polyploid cells. At the end of polyploidization, MK undergo cytoplasmic maturation with important changes in cytoskeleton organization leading to the release of 10 11 platelets per day in the bloodstream. Platelet biogenesis involves the fragmentation of the MK cytoplasm through cytoplasmic extensions called proplatelets that arise from the elongation of the internal membrane powered by microtubule forces. These proplatelets brake into the vascular space due to the blood shear forces and further fragment into preplatelets and platelets in the bloodstream. These cells repair vascular injuries and prevent excessive bleeding. Their generation is tightly controlled by exogenous and endogenous factors.
The role of caspases in MK differentiation remains a controversial issue (Figures 1, 2b and 3b, Table 1 ). 49 It was initially reported that MK died by apoptosis and that the peak of platelet production by MK corresponded to the onset of apoptosis. 50 The thrombocytopenia observed in mice overexpressing Bcl-2 51 or deficient in Bim 52 further argued for an apoptotic component in proplatelet formation. Furthermore, proplatelet formation is impaired in murine MK overexpressing Bcl-X L under control of the platelet factor 4 (PF4) promoter 53 and in human MK cultured with the pan-caspase inhibitor Z-VAD-fmk. 54, 55 Finally, the presence of active caspase-3 in discrete parts of maturing MK cytoplasm suggested that spatially restricted apoptosis could facilitate platelet shedding (Figure 2b ). This punctuated distribution of active caspase-3 contrasted with the diffuse staining observed in apoptotic MK (Table 1) . 55 Amplification of this spatially restricted caspase activation could have explained thrombocytopenia that occurs in patients exposed to toxic, infectious or immune insults as well as in MDS, leading to MK apoptosis before platelet release. 56 Accordingly, an autosomal dominant form of thrombocytopenia was detected in a family with a constitutive variant of cytochrome c (G41S) with enhanced ability to activate caspases, which could accelerate the release of platelets in the bone marrow rather than the bloodstream. 57 In a cell-free system, G41S-increased caspase activation was observed only at low cytochrome c concentrations, suggesting that differentiation-induced caspase activation involves the release of low cytochrome c concentrations in the cytosol, with higher concentrations released in stressful conditions triggering MK apoptosis. However, caspase-9 may be dispensable for these processes, which questions the target of cytochrome c when released in the cytosol of mature MKs. + cells in serum-free medium with 10 ng/ml TPO and 5 ng/ml Stem Cell Factor for 5 days; (c) CD14 + peripheral blood monocytes treated with 100 ng/ml Colony-Stimulating Factor 1 for 3 days. Confocal images were acquired on a Leica SPE Confocal system. The immunofluorescence staining protocol details are found in Solier et al. 112 Scale bar, 5 μm
Both Mcl-1 and Bcl-X L are required to keep Bak and Bax in check in MK. [59] [60] [61] The simultaneous deletion of Bak and Bax, which protects MK from apoptotic stimuli, does not alter thrombopoiesis at steady state or under conditions of stress. 60, 62 It remains unclear how a restricted or localized apoptosis-like process that activates caspases is activated in mature MK and used for platelet shedding, independently of Bak and Bax.
A role of the extrinsic pathway to caspase activation has been suspected as the number of cultured MK that form proplatelets increased when exposed to Fas Ligand or agonistic Fas antibodies or TNF-related apoptosis-inducing ligand (TRAIL), or delivery of a recombinant active form of caspase-8. 54, 63 Accordingly, decreased TRAIL expression in the context of immune thrombocytopenia could reduce proplatelet formation. 64 However, some of these results were obtained in megakaryoblastic cell lines exposed to the poorly specific caspase inhibitor Z-VAD-fmk and further studies showed that, if a FasL-responsive caspase-8-mediated extrinsic apoptosis pathway was operative in MK, this pathway was dispensable for platelet production. 65 Altogether, the restricted or localized apoptosis-like process that may activate caspases in mature MK to promote platelet shedding is independent of the extrinsic pathway.
If there is no strong argument to sustain the initial hypothesis that mature MK may undergo classical apoptosis to promote platelet shedding, caspases could be activated in mature MK and promote platelet release independently of any cell death program, defining a new, non-apoptotic function of these enzymes. A recent report suggested that endoplasmic 
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Identification of caspase targets that are cleaved in mature MK would be a convincing evidence to support the hypothesis that caspase activation is required for platelet shedding and provide insights on how the localized activation of caspases contributes to platelet formation. One of these targets could be the antiapoptotic protein livin that belongs to the inhibitor of apoptosis proteins (IAP) family. 67 Cleavage of gelsolin and poly adenosine diphosphate (ADP)-ribose polymerase (PARP) was also detected. 55 Importantly, MK maturation and platelet biogenesis can occur independently of TPO in situations of acute platelet need. 68 This interleukin-1 alpha driven, TPO-independent mechanism of platelet production, which yields the rapid release of ∼ 20-fold higher numbers of platelets as compared with the classical mechanism of proplatelet formation, involves the activation of caspase-3 that reduces plasma membrane stiffness through dysregulating tubulin expression, with an oversupply of β1-tubulin. 68 This mechanism is clearly distinct from the tightly regulated changes in the cytoskeleton that lead to TPO-dependent platelet formation. The balance between TPO and IL-1α may determine the cellular programming of MK for thrombopoiesis in response to acute and chronic platelet needs.
Platelets themselves are anuclear cytoplasmic fragments that activate a cell autonomous, intrinsic caspase-dependent apoptotic program when Bcl-X L expression declines with ageing. 13, 49 The major dose-limiting toxicity of the BH3 mimetic drug Navitoclax that inhibits several antiapoptotic proteins including Bcl-X L is thrombocytopenia 69 while ABT--199, a Bcl-2-specific BH3 mimetic, has no significant effect on platelet counts. 70 Finally, platelets demonstrate hemostatic and prothrombotic functions through their ability to adhere and aggregate at sites of vascular injury and to support blood coagulation. The conversion of activated platelets to a procoagulant state is associated with specific biochemical and morphologic changes, some of which being similar to those occurring in apoptotic cells, including exposure of phosphatidylserine at the cell surface, membrane contraction, blebbing and microvesiculation. Upon stimulation with various physiological agonists, the formation of procoagulant platelets involves a calcium-dependent but caspase-independent pathway. 71 In murine platelets, caspase-12, an enzyme localized at the cytoplasmic surface of the MK endoplasmic reticulum was involved in agonist-induced integrin activation in platelets, suggesting a non-apoptotic function of the enzyme that would need further investigation. 72 
Caspases in Monocyte Differentiation into Macrophages
The development of circulating blood monocytes involves the growth factor receptor CSF-1 R (colony-stimulating factor-1 receptor, also known as M-CSFR / CD115) at the surface of hematopoietic stem cells and myelomonocytic cells. Two CSF-1 R ligands have been identified, CSF-1 73 and interleukin-34 (IL-34). 74 IL-34 directs the differentiation of myeloid cells in the skin epidermis and central nervous system. 75 CSF-1 is a monocytic lineage-specific cytokine that directly acts on a hematopoietic stem cell in the bone marrow Caspases in myeloid cell differentiation S Solier et al to instruct a change of cell fate through activation of the endogenous Ets family transcription factor PU.1. 76 Monocytes develop from HSCs via several commitment steps and intermediate progenitor stages that pass through the CMP, the GMP, and the macrophage/dendritic cell progenitor stages (Figure 1 ). PU.1 controls cell fate decisions by engaging in antagonistic interactions with other transcription factors, for example, with GATA-1 to shut down the MK/erythroid pathway, with GATA-2 to inhibit mast cell development, and with C/EBPα to block granulocytic differentiation. 77 An official nomenclature subdivides mature monocytes into subsets with a suspected gradual developmental relationship between them. 78 Over one billion monocytes are produced daily, with a fraction differentiating into macrophages while the others are deleted through a process that may involve the Fas pathway as spontaneous monocyte apoptosis in culture is inhibited by neutralizing antibodies to the death receptor Fas or its cognate ligand FasL 79 and mice deficient in Fas display increased numbers of circulating monocytes. 80 In some tissues such the epidermis (Langerhans cells) and the brain (microglia), macrophages derive from embryonic progenitors and self-maintain by local proliferation during adulthood with no or minimal input from circulating monocytes. 81 In other tissues such as intestinal lamina propria (LP) and dermis, macrophages are replaced from monocytes and many other tissue-resident macrophages reflect an intermediate situation. 82 Monocyte recruitment might occur under conditions of stress and inflammation that deplete the local population and also under homeostatic conditions to maintain the pool of macrophages in a given tissue when local self-renewal capacity becomes gradually exhausted with age. 81 In ex vivo culture, CSF-1-induced differentiation of monocytes into macrophages is associated with caspase activation in the absence of any cell death (Figure 1, 2c and 3c , Table 1 ), 83 and this differentiation can be prevented by the pan-caspase inhibitor Z-VAD-fmk or expression of the viral pan-caspase inhibitor p35, or overexpression of the anti-apoptotic protein Bcl-2. Caspase-8 deletion in mouse bone marrow cells also results in arrest of monocyte differentiation into macrophages. 84 Caspase activation is not detected when circulating monocyte differentiation is induced by granulocyte macrophage colony-stimulating factor (GM-CSF). CSF-1 and GM-CSF are the apex macrophage survival cytokines, with a strong role of GM-CSF in the function of alveolar macrophages and a broader effect of CSF-1. It was therefore paradoxical to detect caspase activation in monocytes treated with a cytokine that is essential for their survival.
CSF-1 interaction with CSF-1 R at the surface of human and murine peripheral blood monocytes in culture provokes the oscillatory activation of phosphatidylinositol-3-kinase and the kinase AKT (Figure 3c) . 85 After several waves of activation, within 2-3 days, a molecular platform is generated. This platform includes the adaptor protein FADD (Fas-associated death domain), RIPK1 (receptor-interacting serine/threonineprotein kinase 1), FLIP (cellular FLICE inhibitory protein) and procaspase-8 (Figure 3c) . 86 The formation of this platform and the subsequent activation of caspase-8 may not require a death receptor as it is not prevented by the expression of a dominant negative mutant of FADD that cannot interact with death receptors. 86 Active caspase-8 may directly cleave RIPK1, which turns down NF-κB activity (Figure 3c ). 86 Caspase-8 also activates downstream caspase-3 and caspase-7 that cleave a series of selected substrates. Identified targets of caspases in CSF-1-treated monocytes include nucleophosmin (NPM1), the serine/threonine-protein kinase PAK-2 (p21-activated kinase 2), α-tubulin, PAI-2 (plasminogen activator inhibitor-2), several mRNA binding proteins of the hnRNP family (H and C) and vinculin (Table 1) . 87 Several of these targets are involved in cytoskeletal regulation, suggesting a role of their proteolysis in the cytoskeleton reorganization associated with differentiation. Many other typical caspase targets in cells undergoing apoptosis are not cleaved, phosphatidylserine is not exposed at the cell surface, and no DNA fragmentation is detected. 83, 87 The tight regulation of the proteolytic process associated with differentiation is illustrated by the proteolysis of NPM1, a ubiquitously and abundantly expressed 38-kDa Box 2 Deregulated interplay between GATA-1, HSP70 and caspases as a pathogenic mechanism of anemia in myelodysplastic syndromes (MDS) and β-thalassaemia MDS are clonal disorders of the HSC in which ineffective hematopoiesis is responsible for peripheral blood cytopenias. Anemia is the consequence of a dyserythropoiesis that associates defective maturation and excessive apoptosis of erythroid precursors. The decreased GATA-1 expression observed in MDS erythroblasts correlates with a defect of HSP70 accumulation in erythroblast nucleus. GATA-1 expression can be restored by addition of pan-caspase inhibitors to erythroid cultures and erythroid differentiation is restored by expression of a mutated GATA-1 that cannot be cleaved by caspases or a mutated HSP70 targeted to the cell nucleus. 44 It remains to be determined if defective Epo signaling is responsible for the abnormal shuttling of HSP70 to the nucleus or other pathways that regulate HSP70 localization are altered as a consequence of somatic mutations that accumulate in the HSC. Of note, caspase inhibition does not restore erythroid colony formation in early stage MDS, possibly because it blocks erythroid differentiation. 45 In β-thalassaemia, HSP70 is sequestrated in the cytoplasm as it interacts with free α-globin chains of hemoglobin that accumulate as a consequence of the quantitative defect in the synthesis of β-globin chains. Again, the maturation of human β-thalassaemia major erythroblasts with a nuclear targeted HSP70 or a mutated GATA-1 that resists to caspase-3-mediated cleavage restores terminal erythroid maturation. 46 In these two diseases, alteration of the GATA-1/ HSP70 interplay suggests therapeutic approaches that could restore the nucleocytoplasmic shuttling of HSP70.
phosphoprotein that shuttles between the granular region of the nucleolus and the cytoplasm, especially during the S phase of the cell cycle. 88 This chaperone protein and transcription co-regulator is a caspase substrate in cells undergoing apoptosis. 88 In CSF-1 treated monocytes, caspase-7 cleaves NPM1 at D213 to generate a 30-kDa N-terminal fragment, and the protein is further cleaved into a 20-kDa fragment by cathepsin B.
89 NPM1 fragments contribute to the limited motility, migration and phagocytosis capabilities of resting macrophage and the proteolysis of NPM1 by caspase-7 and cathepsin B participates in the establishment of a mature macrophage phenotype. TLR4-mediated activation of macrophages inhibits the proteolytic processes and restores expression of the full-length protein that negatively regulates the transcription of cytokines genes implicated in inflammation. In mice with heterozygous NPM1 gene deletion, cytokine production in response to lipopolysaccharide is dramatically enhanced. 89 Macrophage polarization plays an important role in the pathogenesis of diverse human diseases. 90 In a bleomycininduced lung fibrosis model, a caspase inhibitory molecule was shown to prevent the development of lung fibrosis, 91 but additional studies are needed to determine if a change in the polarization of lung macrophages account for this effect.
In addition to activating caspases, engagement of CSF-1 R in monocytes elicits typical autophagy. [92] [93] [94] In the absence of ATG7, differentiation of monocytes into macrophages is severely impaired with perturbed acquisition of specific macrophage functions such as bacteria phagocytosis. 93 On the contrary to caspase activation however, accumulation of LC3-II, increased expression of SQSTM1/p62 and enhanced activity of cathepsins that characterize autophagy are observed in monocytes treated with GM-CSF. 95 Many stress pathways induce autophagy, and apoptosis within the same cell, usually in a sequence in which autophagy precedes apoptosis. 96 These processes cross-regulate each other, mostly in an inhibitory manner, that is, autophagy blocks the induction of apoptosis until caspase activation shuts off the autophagic process. Mitophagy and the interaction of sequestosome 1 (SQSTM1 or p62) with ubiquitylated proteins are two ways for autophagy to prevent apoptosis, but the dialogue between autophagy and caspase-dependent cell death is context-dependent. CSF1-induced differentiation of monocytes into macrophages may represent a unique model in which autophagy efficiently restrains caspase activation to prevent cell death. Both ATG5 and SQSTM1, which are involved in autophagy, were co-localized with caspase-8, FADD, FLIP and RIPK1, suggesting that initiation of autophagy and caspase activation could occur in the same cell compartment. 97 Monocytes are key actors of innate and adaptive immune responses through the production of IL-1β. The proteolytic activating cleavage of pro-IL1β is most commonly executed by caspase-1 whose activity is controlled by the formation of the inflammasome. Typically, this process leads to pyroptosis through caspase-1-mediated cleavage of the effector molecule GSDMD (Gasdermin-D). Human monocytes can secrete mature IL-1β in response to lipopolysaccharide through an alternative inflammasome activation that relies on TLR4-TRIF-RIPK1-FADD-CASP8 to propagate activation to NLRP3, a pathway that does not lead to cell death. 15 Active Caspase-3 in Mast Cell Granules Active caspase-3 was recently identified in human mast cells in the absence of apoptosis. GMP give rise to basophil-mast cell progenitors (BMCP, CD34 + , CD13 + , FcεRI − , KIT + ) in the bone marrow. These progenitors circulate in the peripheral blood as agranular mononuclear leukocytes and complete their maturation into peripheral tissues where they acquire phenotypic diversity. SCF is the most important cytokine involved in mast cell development, driving their homing, proliferation, survival and differentiation. Different mast cell phenotypes finally develop in vascular tissues and organs, containing tryptase alone or both tryptase and chymase along with other proteases in their lysosome-like secretory granules. 98 These cells are important effector cells of the immune system that, like many other bone-marrow-derived hematopoietic cells, die through a caspase-dependent apoptotic process. 99, 100 Enzymatically active caspase-3 was not detected in BMCPs but appeared to accumulate during the process of mast cell maturation ( Table 1 ). The enzyme was located in subcellular fractions containing secretory granulelocalized proteases and rapidly released into the cytosolic compartment after permeabilization of the secretory granules upon mast cell activation.
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Concluding Remarks
Non-apoptotic functions of caspases contribute to the differentiation of erythroid cells, the maturation of proplatelets, the release of platelets and the functions of mast cells and CSF-1 induced macrophages, suggesting fine-tuned adaptive processes triggered by cytokines and chemokines. A nonapoptotic function of caspase-3 was also detected in bone marrow stromal stem cells 103 and hematopoietic stem cells, 104 suggesting that this enzyme could be a gatekeeper of stem cell functions. The loss of caspase-3 favors HSC proliferation while decreasing their differentiation, in part through modifying their response to exogenous signals provided by their environment, 104 a phenotype partially rescued by the deletion of p21 cip1/waf1 . 105 Caspase-2 knock-out also affects mouse HSC behavior by promoting their myeloid differentiation but the molecular pathway involved remain unknown. 106 The relevance of these observations in healthy and diseased human HSC his unclear.
The non-apoptotic functions of caspases raise compelling questions of how the activity of these death-associated enzymes is controlled to maintain cell integrity. Much of the regulation of apoptotic functions of caspases may be carried out by IAPs, but there is still little evidence that these ubiquitin ligases are involved in the regulation of their non-apoptotic functions. 107 Some cells resist caspase-mediated cell death by sequestering caspase activity in specific subcellular regions, as described in Drosophila spermatids, 108 insect neuronal dendrites, 109 and megakaryocytes. 55 Caspase activation can also be very transient and coordinated with the chaperoning of key proteins for cell survival and differentiation, as observed in the erythroid lineage. Finally, the biochemical mechanisms leading to caspase activation could differ during differentiation and cell death, for example, conformational changes without cleavage could activate these enzymes. 110 The dynamics of caspase activation in differentiating cells is still poorly understood. While the signaling cascade activated by CSF-1 in monocytes has been partially identified, going through waves of PI-3 K signaling with increasing duration and amplitude to finally promote the formation of a cytosolic multimolecular platform in which caspase-8 is recruited and activated, it remains unclear how TPO and Epo activate non-apoptotic caspases in differentiating MK and basophilic erythroblasts respectively. With some exceptions, the contribution of most of the caspase substrates cleaved in these non-apoptotic settings remains poorly explored. Finally, with the ermergence of clinically tested caspase inhibitors, 111 a central question will be to determine if these enzymes could be therapeutically manipulated to restore or inhibit specific differentiation pathway, for example, to modulate immune cell polarization.
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